Találati lista | Tudóstér

001-es BibID:	BIBFORM125841
Első szerző:	Sebbag, Eden
Cím:	EULAR Points to Consider on the initiation of targeted therapies in patients with inflammatory arthritis and a history of cancer / Eden Sebbag, Kim Lauper, Juan Molina-Collada, Daniel Aletaha, Johan Askling, Karolina Gente, Heidi Bertheussen, Samuel Bitoun, Ertugrul Cagri Bolek, Gerd R. Burmester, Helena M. Canhão, Katerina Chatzidionysiou, Jeffrey R. Curtis, Francois-Xavier Danlos, Vera Guimarães, Merete Lund Hetland, Florenzo Iannone, Marie Kostine, Tue Wenzel Kragstrup, Tore K. Kvien, Anne Constanze Regierer, Hendrik Schulze-Koops, Lucia Silva-Fernandez, Zoltan Szekanecz, Maya H. Buch, Axel Finckh, Jacques-Eric Gottenberg
Dátum:	2024
ISSN:	0003-4967
Megjegyzések:	Background Potential associations between targeted therapies and a new cancer in patients with inflammatory arthritis (IA) and a previous malignancy are a frequent concern in daily rheumatology practice. Objectives To develop points to consider (PTC) to assist rheumatologists when initiating a targeted therapy in the context of a previous malignancy.Methods Following EULAR standardised operating procedures, a task force met to define the research questions for a systematic literature review and to formulate the overarching principles (OPs) and the PTC. Results The group formulated five OPs; seven PTC were formulated concerning the initiation of targeted therapies in patients with active IA and a previous malignancy in remission and one PTC concerning patients with active IA who were not in cancer remission. Major themes included (a) the need to assess the individualised risk of cancer recurrence based on the characteristics of the patient, cancer and the underlying disease; (b) the importance of engaging with specialists caring for cancer and defining treatment based on a shared decision between the patient and the rheumatologist; (c) the value of initiating without delay an appropriate targeted therapy for the treatment of the IA in patients in remission of their cancer; (d) the proposal to use Janus kinase inhibitors and abatacept with caution and in the absence of therapeutic alternatives, based on the absence of any data concerning their use in the context of previous malignancy. Conclusion The 2023 EULAR Points to Consider provide guidance on the management of targeted therapies in patients with IA and a previous malignancy.
Tárgyszavak:	Orvostudományok Elméleti orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban folyóiratcikk
Megjelenés:	Annals Of The Rheumatic Diseases. - "Accepted by Publisher" (2024). -
További szerzők:	Lauper, Kim Molina-Collada, Juan Aletaha, Daniel Askling, Johan Gente, Karolina Bertheussen, Heidi Bitoun, Samuel Bolek, Ertugrul Cagri Burmester, Gerd R. Canhão, Helena M. Chatzidionysiou, Katerina Curtis, Jeffrey R. Danlos, Francois-Xavier Guimarães, Vera Hetland, Merete Lund Iannone, Florenzo Kostine, Marie Kragstrup, Tue Wenzel Kvien, Tore K. Regierer, Anne Constanze Schulze-Koops, Hendrik Silva-Fernández, Lucía Szekanecz Zoltán (1964-) (reumatológus, belgyógyász, immunológus) Buch, Maya H. Finckh, Axel Gottenberg, Jacques-Eric
Internet cím:	DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon: